Navigation Links
Rapid Increase In Sclerosant Use Will Drive Steady Expansion Of US Varicose Vein Treatment Device Market
Date:4/4/2013

TORONTO, April 4, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, growth in the United States market for varicose vein treatment devices will be driven largely by strong growth in the sclerotherapy market segment. Although endovenous ablation devices will continue to generate the most revenue in the varicose vein treatment device market, the sclerotherapy segment will see the strongest market growth; this segment will account for more than a quarter of the total market revenue by 2021.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36799LOGO)

Sclerotherapy agents are versatile and can be applied either as a foam or a liquid. These procedures are also relatively easy for physicians to learn and perform. As a result, many non-surgeons are beginning to adopt these procedures over other treatments, such as endovenous ablation or phlebectomy. In particular, the foam sclerotherapy segment has historically been underpenetrated, and the efficiency, low cost and minimum invasiveness of this procedure will set the stage for rapid adoption through 2021.

The launch of BTG's Varisolve foam sclerosant in mid-2014 will further drive adoption in this segment. This product will represent the first US Food and Drug Administration (FDA)-approved foam sclerosant, and the high profile of this agent will further encourage physicians to use sclerosants over other treatment methods.

"The presence of an FDA-approved foam sclerosant on the market will boost the reputation of these procedures," says MRG Analyst Tonya Martin . "The launch of Varisolve will drive the use of foam for both on-label and off-label procedures, increasing the proportion of physicians using sclerotherapy. It's more rigorously tested and more convenient than the various 'homebrew' foam formulations physicians have been using, so we'll see strong uptake and revenue growth."

Although sclerotherapy will cannibalize sales in the phlebectomy segment, high sclerosant selling prices and strong procedure volume growth will support the steady expansion of the United States market for varicose vein treatment devices through 2021.

Millennium Research Group's US Markets for Varicose Vein Treatment Devices 2013 report includes unit, procedure, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for endovenous ablation devices, surgical stripping devices, phlebectomy devices and sclerotherapy agents in the United States.

About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Christopher Comfort
Decision Resources Group
781-993-2597
ccomfort@dresources.com

Alex Jablokow
Millennium Research Group
617-599-8613
ajablokow@mrg.net


'/>"/>
SOURCE Millennium Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Assurex Health Appoints Chief Financial Officer and Payer Market Executive to Manage Rapid Growth in Personalized Medicine
2. Independent Study Published in Clinical Infectious Diseases Highlights the Importance of Antimicrobial Removal Systems in Blood Culture to Rapidly and Accurately Aid in the Diagnosis of Sepsis
3. Fuisz Pharma Announces Patent Allowance For New Tablet And Caplet Shapes That Promote Rapid, Reliable Esophageal Transit
4. Frost & Sullivan: U.S. Health Information Exchange Market Enters Prime Time in Rapidly Transforming Healthcare Industry
5. Abacus Diagnostica Receives CE Mark for its Rapid Direct PCR Test for Toxigenic Clostridium Difficile
6. Artificial disc brings increased mobility and rapid recovery to patients suffering chronic neck pain in the Midwest
7. Epidemiology: Rheumatoid Arthritis in China - Rapid urbanization presents favorable market potential
8. Biodel Announces Phase 2 Clinical Trial Initiation Of Ultra-Rapid-Acting Insulin Candidate BIOD-123
9. Central Logic Poised for Rapid Expansion with New Financial Partner Mercato Partners
10. UK Hospitals Commence Advanced Stereotactic Lung Cancer Treatments Using RapidArc Radiosurgery
11. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... and Strategies - 2016" report to their offering. ... The latest research Autism ... pricing data and benchmarks in the global Autism Spectrum Disorder market. ... What are the key drugs marketed for Autism Spectrum Disorder ...
(Date:2/23/2017)... Limited, ( ASX: ITD ), an innovative diversified healthcare company, is ... December 2016 compared with the previous corresponding period. A full "Results ... . Highlights Profit after ... Earnings per share of 2.2 cents (Dec 2015: 1.2 cents; up ... 11%) Profit before tax of $2.12m (Dec 2015: ...
(Date:2/23/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The latest research Oesophageal Cancer Drugs Price Analysis ... the global Oesophageal Cancer market. The research answers the ... drugs marketed for Oesophageal Cancer and their clinical attributes? How are ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... An in-depth computational analysis of ... of Pittsburgh points to eight genes that may explain why susceptibility to one of ... results of a study published today in the journal npj Schizophrenia. , “There ...
(Date:2/24/2017)... ... February 24, 2017 , ... Healthcare Associates of ... Center at Craig Ranch building at 8080 State Highway 121, Suite 210, McKinney, Texas ... easy access to Highway 121. , As the practice has grown, the need for ...
(Date:2/24/2017)... ... February 24, 2017 , ... The International Association of Eating Disorders Professionals ... What You See” body image mannequin art competition. Selected from 15 submissions from around ... winner revealed at the 31st annual iaedp Symposium, March 22 – 26 in Las ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... again hosted their Military Wedding Giveaway, with the winning couple announced on Feb. ... with services generously donated from local vendors: A Matter of Taste, Ryan Rousseau ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... with a clinician-based audience, will be participating in Rare Disease Day events, hosted ... D.C. In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, ...
Breaking Medicine News(10 mins):